HIF-PH Encoded by <i>EGLN1</i> Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia

Owing to the recent emergence of drug resistance to Bruton’s tyrosine kinase inhibitors (BTK) in chronic lymphocytic leukemia (CLL) treatment, it is crucial to identify alternative therapeutic targets. Therefore, we aimed to identify therapeutic options for CLL besides BTK. We identified that HIF1A...

Cijeli opis

Bibliografski detalji

Glavni autori:	Wancheng Guo, Daomiao Liang, Peilong Wang, Le Yin, Huifang Zhang, Cheng Xing, Zineng Huang, Yinghua Wu, Heng Li, Zhao Cheng, Xiaojuan Xiao, Jing Liu, Zhihua Wang, Hongling Peng
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2022-06-01
Serija:	Pharmaceuticals
Teme:	CLL hypoxia-inducible factor prolyl hydroxylase (HIF-PH) molidustat <i>EGLN1</i>
Online pristup:	https://www.mdpi.com/1424-8247/15/6/734
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!